---
figid: PMC5190135__oncotarget-07-44790-g001
figtitle: Anticancer properties of nimbolide and pharmacokinetic considerations to
  accelerate its development
organisms:
- Staphylococcus aureus
- Salmonella enterica subsp. enterica serovar Typhimurium
- Chromobacterium violaceum
- Staphylococcus aureus 1-B-1
- Mus musculus
- Rattus norvegicus
- Oryctolagus cuniculus
- Canis lupus familiaris
- Ovis aries
- Cricetus cricetus
- Avian myelocytomatosis virus
- AKT8 retrovirus
- Homo sapiens
- Plasmodium falciparum
- Azadirachta indica
organisms_ner:
- Mus musculus
- Rattus norvegicus
- Homo sapiens
- Oryctolagus cuniculus
- Canis lupus familiaris
- Ovis aries
- Danio rerio
pmcid: PMC5190135
filename: oncotarget-07-44790-g001.jpg
figlink: /pmc/articles/PMC5190135/figure/F1/
number: F1
caption: 'Nimbolide induces apoptosis through diverse molecular mechanism(s). Nimbolide
  disrupts MOMP, which promotes caspases activation leading to apoptosis. Nimbolide
  also reduces the level of CDKs and cyclins, causing cell cycle arrest. Nimbolide
  also abrogates various signaling cascades including MAPK (ERK1/2), JAK2/STAT3 and
  PI3K/Akt, leading to suppression of proliferation of a wide variety of human cancer
  cells. Nimbolide disrupts the Nrf2-KEAP1 complex and promotes the release of Nrf2,
  thus increasing levels of antioxidant and detoxification enzymes. Nimbolide suppresses
  IκBα degradation and prevents nuclear translocation of p65, therefore repressing
  the expression of various genes involved in cell proliferation, anti-apoptosis,
  angiogenesis and metastasis. Inhibition of the NF-κB pathway also reduces the dissociation
  of GSK-3β from β-catenin, hence restraining the Wnt/β-catenin signaling pathway.
  →: activate/induce; Long Left Tack: suppress/inhibit.'
papertitle: Anticancer properties of nimbolide and pharmacokinetic considerations
  to accelerate its development.
reftext: Lingzhi Wang, et al. Oncotarget. 2016 Jul 12;7(28):44790-44802.
year: '2016'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9672695
figid_alias: PMC5190135__F1
figtype: Figure
redirect_from: /figures/PMC5190135__F1
ndex: 92477feb-dece-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC5190135__oncotarget-07-44790-g001.html
  '@type': Dataset
  description: 'Nimbolide induces apoptosis through diverse molecular mechanism(s).
    Nimbolide disrupts MOMP, which promotes caspases activation leading to apoptosis.
    Nimbolide also reduces the level of CDKs and cyclins, causing cell cycle arrest.
    Nimbolide also abrogates various signaling cascades including MAPK (ERK1/2), JAK2/STAT3
    and PI3K/Akt, leading to suppression of proliferation of a wide variety of human
    cancer cells. Nimbolide disrupts the Nrf2-KEAP1 complex and promotes the release
    of Nrf2, thus increasing levels of antioxidant and detoxification enzymes. Nimbolide
    suppresses IκBα degradation and prevents nuclear translocation of p65, therefore
    repressing the expression of various genes involved in cell proliferation, anti-apoptosis,
    angiogenesis and metastasis. Inhibition of the NF-κB pathway also reduces the
    dissociation of GSK-3β from β-catenin, hence restraining the Wnt/β-catenin signaling
    pathway. →: activate/induce; Long Left Tack: suppress/inhibit.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Tnf
  - Il6
  - Egf
  - Chuk
  - Gsk3b
  - Ctnnb1
  - Trp53
  - Rela
  - Gorasp1
  - Cdc37
  - Lsp1
  - Nfkb1
  - Pold2
  - Cd40
  - Dctn2
  - Akt1
  - Cdkn1a
  - Nsg1
  - Tpt1
  - Tceal1
  - Mapk3
  - Mapk1
  - Keap1
  - Bel
  - Nit2
  - Tef
  - Ccnd1
  - Myc
  - Nol3
  - Bcl2
  - Bc1
  - Bc1-ps1
  - Igkv1-136
  - Bcl2l1
  - Xiap
  - Mmp9
  - Icam1
  - Vegfa
  - Stat3
  - Igf1
  - Tp53
  - Syt1
  - Kras
  - IGF1
  - TNF
  - IL6
  - EGF
  - JAK1
  - JAK2
  - JAK3
  - TYK2
  - CHUK
  - GSK3A
  - GSK3B
  - CTNNB1
  - NFKBIA
  - TP53
  - TP63
  - TP73
  - RELA
  - SYT1
  - GORASP1
  - WNK1
  - CD40
  - ARHGEF7
  - ASCC1
  - H3P40
  - AKT1
  - AKT2
  - AKT3
  - CDKN1A
  - TCEAL1
  - NSG1
  - H3P16
  - MAPK3
  - MAPK1
  - KEAP1
  - CASP1
  - CASP2
  - CASP4
  - CASP5
  - CASP6
  - CASP8
  - CASP9
  - CASP10
  - CASP12
  - CASP14
  - CASP3
  - CASP7
  - NIT2
  - TEF
  - CCND1
  - MYC
  - BCL2
  - CHMP2A
  - XIAP
  - MMP9
  - ICAM1
  - VEGFA
  - VEGFB
  - VEGFC
  - VEGFD
  - PGF
  - STAT3
  - CCND2
  - BCL-2
  - ICAM-1
  - BCL2L1
  - igfn1.2
  - tnfb
  - egf
  - celsr1a
  - il6
  - gsk3ba
  - gsk3ab
  - ctnnb1
  - tp53
  - rela
  - nfkb1
  - cdkn1a
  - mapk3
  - keap1a
  - lhx2b
  - hbbe1.1
  - hbbe1.2
  - nit2
  - tefa
  - ccnd1
  - myca
  - chmp2a
  - bcl2a
  - xiap
  - mmp9
  - vegfaa
  - stat3
  - Cancer
---
